Blood-based biomarkers hold great promise to revolutionize the diagnostic and prognostic
work-up of Alzheimer's disease (AD) in clinical practice. This is very timely, considering the …

Summary Sporadic Creutzfeldt-Jakob disease is a fatal neurodegenerative disease caused
by misfolded prion proteins (PrP Sc). Effective therapeutics are currently not available and …

Accumulating data from the clinical research support that the core Alzheimer's disease (AD)
cerebrospinal fluid (CSF) biomarkers amyloid‐β (Aβ42), total tau (T‐tau), and …

Alzheimer's disease (AD) is a progressive neurodegenerative disease with a complex and
heterogeneous pathophysiology. The number of people living with AD is predicted to …

Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology
at the earliest stage of some neurodegenerative disorders, but do not have the scalability …

Several potential disease-modifying drugs for Alzheimer's disease (AD) have failed to show
any effect on disease progression in clinical trials, conceivably because the AD subjects are …

Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …

Background Phosphorylated tau (p-tau) epitopes in cerebrospinal fluid (CSF) are accurate
biomarkers for a pathological and clinical diagnosis of Alzheimer's disease (AD) and are …

Tau is a protein that associates with microtubules (MTs) and promotes their assembly and
stability. The protein loses its ability to bind MTs in tauopathies, and detached tau can …

Synapses are the site for brain communication where information is transmitted between
neurons and stored for memory formation. Synaptic degeneration is a global and early …